Xenon Pharmaceuticals Provides Update On Partnered Program With Neurocrine Biosciences
Portfolio Pulse from Benzinga Newsdesk
Xenon Pharmaceuticals announced that its partner, Neurocrine Biosciences, reported that the Phase 2 clinical trial evaluating NBI-921352 in adult patients with focal onset seizures failed to demonstrate meaningful reduction in seizure frequency. No further development with NBI-921352 in FOS is planned at this time. Xenon intends to work closely with Neurocrine to review the data and understand any potential implications for the second ongoing study with NBI-921352 in SCN8A-developmental epileptic encephalopathy.
November 09, 2023 | 10:03 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
The failure of the Phase 2 clinical trial of NBI-921352, a drug developed in partnership with Neurocrine Biosciences, could negatively impact Xenon Pharmaceuticals' stock in the short term.
The failure of a Phase 2 clinical trial is a significant setback for any biopharmaceutical company. This could lead to a decrease in investor confidence and a potential drop in Xenon's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100